NHMRC CRE for ANZMUSC

We are pleased to announce that ANZMUSC has been awarded an NHMRC Centre for Research Excellence (CRE) at the last funding round in 2017.

The ANZMUSC Centre of Research Excellence (CRE) was officially launched by the Hon. Greg Hunt MP, Federal Minister for Health on Thursday 22nd March 2018 at the Cabrini Institute in Melbourne. The event was officiated by Dr Michael Walsh, CEO of Cabrini Health. Speakers included Professor Marc Parlange, Provost and Senior Vice-President of Monash University, and Dr Andrew Black, Director of Research Development and Collaboration in the Office of the Deputy Vice-Chancellor Research at The University of Sydney.

ANZMUSC CRE Seeding Grant applications open

The ANZMUSC Seeding Grant Funding Scheme is funded from the ANZMUSC NHMRC Centre of Research Excellence grant. Seed funding is granted for research projects that can achieve a tangible outcome within 12 months of receipt of grant funds.

  • Applications are due June 30th 2018. Application requires one electronic copy via email to admin@anzmusc.org
  • Awards will be announced on 1st Sep 2018.
  • Investigators must be registered members of ANZMUSC.
  • Preference will be given to applications that seem more likely to secure future external funding
  • The maximum funding that can be requested is $10,000. We anticipate awarding a total of 3 grants
  • Funding is untied and must be incurred or committed in 2019.
  • Applications will be judged based upon project merit (Scientific Quality, Significance & Innovation, Consumer involvement in proposal development, Team Quality and Capability)
  • Chief Investigators on the ANZMUSC NHMRC CRE are ineligible to apply.

Please click HERE for more information on the seeding grant guidelines and to submit your application.

2018 Annual Scientific Meeting Report

The 2018 ANZMUSC Annual Scientific Meeting held in Melbourne was attended by 75 participants representing 18 universities and research institutes, 14  professional associations, health insurance and consumer organisations, and 6 public hospitals.

Invited speakers included Prof John Zalcberg from ACTA, Prof Chris Reid from ANZACT, A/Prof Manuela Ferreira from the Kolling Institute, Ms. Anneliese Synnot from the Cochrane Consumers & Communication Review Group, Prof Lyn March from the University of Sydney, Mr Mick Gooda, Former Aboriginal and Torres Strait Islander Social Justice Commissioner, Prof Rebecca Ivers from the University of New South Wales, Ms Julia Medew – Walkley Award-winning journalist and Dr Ivan Lin from the University of Western Australia.

The two-day Scientific meeting also included the ANZMUSC CRE launch by Hon Greg Hunt, Federal Minister for Health on the second day.

 A detailed report of the scientific meeting can be found here.

 

2018 Finalist for ACTA Trial of the Year and Honourable Mention in ACTA STInG Excellence in Trial Statistics Award

ANZMUSC is proud to announce one of its trials, the PRECISE (Pregabalin in Addition to Usual care for Sciatica) Trial was awarded the 2018 Finalist for ‘Trial of the Year’ sponsored by the Australian Clinical Trials Alliance (ACTA). This award is in “recognition of  outstanding achievement in an investigator-initiated clinical trial”. PRECISE was also awarded finalist in ACTA STInG (Statistics in Trials Interest Group) Excellence in Trial Statistics Award.
The award was presented to A/Prof Christine Lin (Principal Research Fellow, Musculoskeletal Health Sydney, School of Public Health, The University of Sydney) and Prof Jane Latimer (Deputy Director, Musculoskeletal Health Sydney, School of Public Health, The University of Sydney) by the Hon. Greg Hunt MP, Federal Minister for Health at the Clinical Trials 2018 National Tribute & Awards Ceremony held at the Royal Melbourne Hospital on Wednesday 16th of May.

The PRECISE trial was the first trial to rigorously examine the efficacy and safety of pregabalin in sciatica, and provided unequivocal evidence against its use for this condition. The results ruled out any clinically worthwhile treatment benefits and showed that taking pregabalin is associated with an increased risk of adverse events compared to placebo in patients with moderate to severe sciatica. The results were published in the New England Journal of Medicine.

PRECISE was led by a team of investigators who are ANZMUSC members based at The University of Sydney and The George Institute for Global Health.

We congratulate the PRECISE study team on their success, and for being the first ANZMUSC trial to receive this award.

A/Prof Christine Lin (The University of Sydney), Hon Greg Hunt MP, Prof Jane Latimer (The University of Sydney)